LVW Advisors LLC Has $396,000 Stock Position in Stryker Corporation $SYK

LVW Advisors LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 12.4% in the second quarter, Holdings Channel reports. The firm owned 1,000 shares of the medical technology company’s stock after buying an additional 110 shares during the quarter. LVW Advisors LLC’s holdings in Stryker were worth $396,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Nuveen LLC acquired a new position in Stryker during the first quarter worth approximately $558,075,000. Price T Rowe Associates Inc. MD increased its position in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares during the last quarter. Alliancebernstein L.P. increased its position in Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after buying an additional 549,643 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after purchasing an additional 361,136 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SYK has been the topic of several research reports. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Wells Fargo & Company upped their target price on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Rothschild & Co Redburn began coverage on Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Finally, Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Friday. Fourteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $430.33.

Stryker Stock Up 0.1%

Shares of SYK opened at $368.83 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The stock has a market capitalization of $141.01 billion, a price-to-earnings ratio of 48.85, a PEG ratio of 2.66 and a beta of 0.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a fifty day moving average of $385.71 and a 200-day moving average of $379.08.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Insider Activity

In other Stryker news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.